- Investing.com
Invion Limited, a clinical-stage life-sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, and solid cancers, such as lung, ovarian, anogenital, and glioblastoma multiforme cancers. It has a research and development agreement with Hudson Institute of Medical Research to develop a novel photosensitiser for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion’s IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Metrics to compare | IVX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIVXPeersSector | |
---|---|---|---|---|
P/E Ratio | −4.8x | −3.0x | −0.6x | |
PEG Ratio | 0.02 | 0.00 | 0.00 | |
Price/Book | 1.9x | 2.1x | 2.6x | |
Price / LTM Sales | 7.3x | 4.3x | 3.2x | |
Upside (Analyst Target) | 516.7% | 115.4% | 48.4% | |
Fair Value Upside | Unlock | 16.9% | 6.8% | Unlock |